Shockwave Medical — Merger or Acquisition (April 2024)
27 slides from Shockwave Medical's merger presentation, Apr 5, 2024
Slide 1: Investor Presentation April 5, 2024
The following is an investor presentation published by Johnson & Johnson on April 5, 2024 relating to the Acquisition. Investor Presentation April 5, 2024
Slide 2: Cautions Concerning Forward-Looking Statements
Cautions Concerning Forward-Looking Statements This communication contains “forward-looking statements” regarding the acquisition of Shockwave by Johnson & Johnson. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future e
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This communication may be deemed to be solicitation material in respect of the proposed acquisition of Shockwave Medical by Johnson & Johnson. In connection with the proposed transaction, Shockwave intends to file relevant materials with the U.S. Securitie
Slide 4: Agenda and Today's Speakers
Agenda Today’s Speakers CEO Remarks Shockwave Medical Overview Strategic Rationale Financial Impact Joaquin Duato Tim Schmid Joe Wolk Chairman and Chief Executive Executive Vice President, Executive Vice President, Q&A Officer Worldwide Chairman, MedTech Chief Financial Officer Doug Godshall Preside
Slide 5: Joaquin Duato, Chairman and Chief Executive Officer
Joaquin Duato Chairman and Chief Executive Officer, Johnson & Johnson 5
Slide 6: Enhancing our Impact in Cardiovascular Health
Enhancing our Impact in Cardiovascular Health Strengthens J&J presence in high-growth cardiovascular segments Complementary fit with Abiomed heart recovery platform Advances standard of care for patients with cardiovascular disease by growing global reach and scale Shockwave Medical’s segment-leadin
Slide 7: Our Credo
Credomme To Mhovetus WNostro es Credo Fraiat et ne nme geist neataeeeentermrntt os eS - miteetnieartarne Sa —E—EEE= mpeeermeeeenee een cont resmemneir — a SSS venetian Somtae SRS a Ss Soest ieceertteatiset aS : = Best ertrenetecrreoraen soe uen en ores pectoral ope seater pecan po eaceceeay Our Cred
Slide 8: Doug Godshall, President and CEO, Shockwave Medical
Doug Godshall President and Chief Executive Officer, Shockwave Medical 8
Slide 9: IVL helps treat calcified arteries
IVL helps treat calcified arteries How does it work? What is intravascular lithotripsy? A catheter is delivered across a calcified 1 lesion over a wire and a balloon is expanded IVL is a catheter-based treatment for calcified arterial lesions, which can reduce blood flow and cause pain or heart atta
Slide 10: Shockwave Medical Overview
Shockwave Medical Overview A premier medtech growth company transforming the Shockwave Medical today treatment landscape with innovative technologies ~ Sales (~70% CAD, ~30% PAD) $0.7B ~ % YoY Growth (2022-23) 50 Intravascular Lithotripsy (IVL) Robust R&D pipeline Shockwave’s first-to-market technol
Slide 11: Shockwave Medical's Current Portfolio and Pipeline
Shockwave Medical’s Current Portfolio and Pipeline Foundational products established IVL as a safe and effective solution for calcified arterial lesions Developmental Programs in 2023 27 Coronary Peripheral 6 2 Shockwave L (30mm) Shockwave C (12mm) Early Stage 8 FDA 510(k) clearance in 2022 CE Mark
Slide 12: Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech
Tim Schmid Executive Vice President, Worldwide Chairman, MedTech, Johnson & Johnson 12
Slide 13: Cardiovascular disease
Cardiovascular disease #1 $70B 26M cause of death direct medical costs total patients worldwide CARDIOVASCULAR DISEASE presents one of the largest ALL forms of cardiovascular disease lead to heart failure, which is the and most pressing healthcare issues of our lifetime #1 #1 cause of hospitalizatio
Slide 14: Extends J&J MedTech Position in High-Growth Cardiovascular Segments
Extends JJMT Position in High-Growth Cardiovascular Segments PIPELINE OPPORTUNITY Electrophysiology Heart recovery IVL – coronary IVL – peripheral LAAC 14% 20%+ ~20% 13% 20%+ 2023-26 Market 2023-26 Market 2023-26 Market 2023-26 Market 2023-26 Market CAGR CAGR CAGR CAGR CAGR Market Leader: Market Lea
Slide 15: Leveraging J&J's Capabilities to Accelerate Growth
Leveraging Johnson & Johnson’s Capabilities to Accelerate Growth Global Footprint Complementary Strong Professional Deep Regulatory and Well Established to Support OUS with Abiomed Education Market Access Health System and Expansion Technology Capabilities Expertise Physician Relationships 15
Slide 16: Joe Wolk, Executive Vice President, Chief Financial Officer
Joe Wolk Executive Vice President, Chief Financial Officer, Johnson & Johnson 16
Slide 17: Transaction Bolsters Growth Platform
Transaction Bolsters Growth Platform Accelerates revenue growth for Johnson & Johnson and Johnson & Johnson MedTech Accretive to operating margin for Johnson & Johnson and Johnson & Johnson MedTech Dilutive to adj. EPS by ~$0.10 in 2024 and ~$0.17 in 2025, considering impact of financing costs 17
Slide 18: Transaction Details and Path to Close
Transaction Details and Path to Close Expected to close by mid-year 2024 • $335.00 per share in cash Transaction Structure • $13.1 billion enterprise value including cash acquired • Expected to be funded through combination of cash on hand and Sources of debt Financing • Expected to maintain strong
Slide 19: Shockwave Medical Highlights
Johnson & Johnson + Shockwave Medical Highlights Aligns with Brings lifesaving Johnson & Johnson innovations to more strategic priorities patients with unmet needs Accelerates growth Compelling for of Johnson & Johnson and both Shockwave Medical Johnson & Johnson and Johnson & Johnson MedTech shareh
Slide 20: Questions
Questions
Slide 21: Social media posts relating to the Acquisition
4. The following are social media posts of Johnson & Johnson published on April 5, 2024 relating to the Acquisition. Johnson & Johnson LinkedIn :
Slide 22: J&J LinkedIn post
Johnson & Johnson + Follow + 4h-® #NEWS: Today we announced an agreement to acquire Shockwave Medical, a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease. With our focus on Innovative Medicine and MedTech, Johnson & Johnson
Slide 23: MedTech LinkedIn
Johnson & Johnson MedTech LinkedIn :
Slide 24: MedTech LinkedIn posts
Johnson & Johnson MedTech + Follow #NEWS: Today Johnson & Johnson announced an exciting agreement to acquire Shockwave Medical, a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, We look forward to working with the Shockwa
Slide 25: Joaquin Duato LinkedIn post
+ Follow e Joaquin Duato [i 1+ ® Today Johnson & Johnson announced its plans to acquire Shockwave Medical, 2 pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease. The acquisition of Shockwave and its leading IVL technology prov
Slide 26: Email from Tim Schmid to Shockwave employees
5. The following is an email message from Tim Schmid of Johnson & Johnson to Shockwave employees sent on April 5, 2024.
Slide 27: Shockwave Medical Team email
Shockwave Medical Team, On behalf of everyone at Johnson & Johnson, we look forward to welcoming you to our organization. We all know that cardiovascular disease is one of the most pressing healthcare issues of our lifetime, and we deeply admire the innovative progress Shockwave Medical has made in
Shockwave Medical — Merger or Acquisition (April 2024) on 6ix